Hologic CFO Departs; Interim CFO Appointed

TL;DR

Hologic CFO Michael Watts is out Dec 13, Kevin Ryan steps in as interim CFO with a new employment agreement.

AI Summary

Hologic, Inc. announced on December 6, 2024, the departure of its Chief Financial Officer, Michael J. Watts, effective December 13, 2024. The company has appointed Kevin J. Ryan as interim CFO. Additionally, Hologic has entered into a new employment agreement with Ryan, effective December 6, 2024, outlining his compensation and responsibilities during his interim role.

Why It Matters

The sudden departure of a CFO can signal internal challenges or strategic shifts, while the appointment of an interim CFO provides continuity during the search for a permanent replacement.

Risk Assessment

Risk Level: medium — A CFO departure, especially without immediate permanent replacement, can create uncertainty regarding financial strategy and leadership stability.

Key Players & Entities

• Hologic, Inc. (company) — Registrant
• Michael J. Watts (person) — Chief Financial Officer departing
• December 13, 2024 (date) — Effective date of CFO departure
• Kevin J. Ryan (person) — Appointed interim Chief Financial Officer
• December 6, 2024 (date) — Effective date of interim CFO employment agreement

FAQ

Filing Documents

• ef20039609_8k.htm (8-K) — 31KB
• ef20039609_99-1.htm (EX-99.1) — 7KB
• 0001140361-24-048805.txt ( ) — 172KB
• holx-20241206.xsd (EX-101.SCH) — 4KB
• holx-20241206_lab.xml (EX-101.LAB) — 21KB
• holx-20241206_pre.xml (EX-101.PRE) — 16KB
• ef20039609_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 6, 2024, the Board of Directors (the "Board") of Hologic, Inc. (the "Company"), upon the recommendation of the Company's Nominating and Corporate Governance Committee, increased the size of the Board from nine to ten directors and appointed Martin Madaus as a director of the Company, effective December 6, 2024. Dr. Madaus currently serves as an Operating Executive at the Carlyle Group, a global investment firm. Dr. Madaus, who will stand for election by stockholders at the Company's 2025 Annual Meeting of Stockholders, has been appointed to serve on the Company's Compensation Committee and Nominating and Corporate Governance Committee, effective December 6, 2024. As a non-employee director of the Company, he will receive compensation as described in the "Director Compensation" section of the Company's most recent definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the "Commission") on January 18, 2024. Dr. Madaus is also expected to enter into the Company's customary indemnification agreement for directors, in substantially the form filed as Exhibit 10.1 to the Company's Form 8-K filed with the Commission on March 6, 2009. There are no arrangements or understandings between Dr. Madaus and any other persons pursuant to which Dr. Madaus was selected as a director. Dr. Madaus has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. A copy of the Company's press release announcing the election of Dr. Madaus is filed with this Current Report on Form 8-K as Exhibit 99.1.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release dated December 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 9, 2024 HOLOGIC, INC. By: /s/ John M. Griffin John M. Griffin General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR